Ruxolitinib compared with best available therapy for essential thrombocythaemia patients resistant or intolerant to hydroxycarbamide in majic: an investigator lead randomized trial
Κύριοι συγγραφείς: | , , , , , , , , , , , , , , , |
---|---|
Μορφή: | Conference item |
Έκδοση: |
Ferrata Storti Foundation
2016
|